Formerly ZIMMER HOLDINGS INC
Spin-offSpun off from Bristol-Myers SquibbBMYNYSE
The two companies
Open either company's hub for its full SEC financials, ratios, ownership, filings, and every other event it's been part of.
- Sector
- Healthcare
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Exchange
- NYSE
- State of incorporation
- DE
- Record date
- July 27, 2001
- Distribution date
- August 6, 2001
- Ratio
- 1:10
- Parent sector
- Pharmaceutical Preparations
- Form
- 10-12B/A
- Filed
- July 12, 2001
Financials — parent vs spin-off
SEC XBRL · latest year- Revenue
- $48.19B
- Operating income
- —
- Net income
- $7.05B
- Total assets
- $90.04B
- Equity
- $18.47B
- Revenue
- $8.23B
- Operating income
- $1.10B
- Net income
- $705M
- Total assets
- $23.09B
- Equity
- $12.70B
Latest reported figures from each company's own SEC filings — the parent after the separation and the spin-off as a standalone. Full multi-year history on each company hub.
Spin-off signals
score 3/8 favorable · factors, not advice- Focus-increasingNo — both Healthcare
Spin-offs into a different sector than the parent (pure-plays) have historically outperformed diversifying ones.
- Size vs parent (revenue)~17% of parent
Smaller spin-offs draw more forced selling from holders who can't keep them — the classic mispricing edge.
- Leverage (liabilities/assets)45%
A heavy debt load loaded onto the spin-off is a known risk; a clean balance sheet is favorable.
- Return on capital employed5.4%
EBIT ÷ capital employed — the quality metric the spin-off scorecard research weighs most.
- Operating margin13%
Profitability of the standalone business, from its own SEC filings.
- Tax-basis reportNone found
A Form 8937 (basis allocation) accompanies tax-free §355 spin-offs — favorable for taxable holders.
- Insider buying (post-spin)None recorded
Officers/directors buying their own newly independent shares (Form 4) has historically preceded outperformance.
- Time since spin-off24.8 years
Studies find the spin-off return premium concentrates in roughly the first one to three years.
Factors the spin-off research literature (Greenblatt; Cusatis-Miles-Woolridge; Desai-Jain) associates with outcomes — computed from this company's own SEC filings, shown as factors, not a recommendation. The premium is debated and not guaranteed. How we compute these ↗
Filings & documents
Every entry traces to SEC EDGAR. The Information Statement is the primary source; the links below open the full filing and each company's complete filing history.